StockNews.AI
ANGO
StockNews.AI
18 hrs

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

1. AngioDynamics reported Q1 fiscal 2026 sales of $75.7 million, reflecting growth. 2. The company's focus is on enhancing vascular health and cancer treatment options.

Earnings
+6.05%Current Return
VS
+0.12%S&P 500
$11.0710/02 06:07 AM EDTEvent Start
$11.7410/02 11:08 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The positive sales growth could lead to increased investor confidence, similar to past quarters where growth led to stock appreciation.

How important is it?

The positive financial results provide reassurance about the company's growth trajectory, influencing investor decisions.

Why Short Term?

Q1 results typically affect stock prices immediately; historical data shows investor reaction to earnings reports is rapid.

Related Companies

VRTXAVEOISRG
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Fiscal Year 2026 First Quarter Highlights   Quarter Ended August 31, 2025 Pro Forma* YoY Growth Net Sales $75.7 million.

Related News